Activity Outline

FDA Grand Rounds: Ethnicity- and Gender-related Differences in Alzheimer's Disease

January 11, 2018
12:00 PM - 1:00 PM
FDA White Oak Building 2 / Central Shared Use Building (CSU) Room 2031

Series Description

The FDA Grand Rounds is webcast every other month to highlight cutting-edge research underway across the agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities.

Lecture Description

Minorities and women are particularly vulnerable to Alzheimer's disease (AD). Current Alzheimer's Association President and CEO Harry Johns noted that relative to Caucasians "the threat [of AD] is even more substantial in the African-American and Hispanic communities." This is partially related to the higher incidence of dementia and AD as well as increased severity of symptoms in African Americans. That increased incidence or risk remains high, despite adjustments for education, family dementia histories, and hypertension co-morbidity. Socioeconomic status, other health conditions, health care access, and delays in physician consultation likely contribute to--but do not explain--all those disparities.

Increased research into African Americans and other minority populations with AD is crucial to the goals of precision medicine and yet this is traditionally an understudied population. This does, however, appear to be changing. Studies indicate the advantage of using different approaches to understanding what is likely to be a complex picture of AD-related ethnicity differences.

Women have a higher incidence of AD at later ages. For example, among people who are 71 years of age or older, 16% of women have AD compared with only 11% of men. Better understanding of sex differences involved in the cause and progression of AD could contribute to better drugs and other types of interventions to slow the disease progression.

This presentation will discuss research into protein levels in post-mortem African American and Caucasian brain tissue from both genders to explore ethnicity- and gender-related differences. The selected proteins include those thought to be critically involved in AD. Those proteins were examined in samples of the middle temporal gyrus that were matched for age at death since this region is critically involved in language processing and generation and has been shown to be significantly affected by AD.

References

- Manly, J.J. and R. Mayeux, Ethnic differences in dementia and Alzheimer's disease, in Critical Perspectives on Racial and Ethnic Differences in Health in Late Life, N.A. Anderson, R.A. Bulatao, and B. Cohen, Editors. 2004, National Academy Press: Washington, DC. p. 95-142.
- Alzheimer's, A., 2014 Alzheimer's disease facts and figures. Alzheimer's Dement, 2014. 10(2): p. e47-92.
- Tang, M.X., et al., Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology, 2001. 56(1): p. 49-56.

Series Objectives

- Discuss the research conducted at the FDA
- Explain how FDA science impacts public health

Learning Objectives After completion of this activity, the participant will be able to:

- Explain the neurodegenerative protein differences between African Americans and Caucasians of both genders
- Describe how those protein differences might contribute to the differences in disease severity
- Discuss the advantages of multiplex technology
- Explain the importance of this field of research for Alzheimer's disease as well as others.

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other scientists within the agency and external scientific communities.

Agenda

Lecture 1 January11, 2018

Time	Topic	Speaker
12:00 - 1:00 PM	Ethnicity- and Gender-related Differences in Alzheimer's Disease	Sherry Ferguson and Vijayalakshmi (Viji) Varma, Ph.D.

Continuing Education Accreditation

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number J0002895-0000-18-002-L04-P for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal https:/ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacy participants: partial credit cannot be awarded, therefore you must attend the entire activity to receive CPE credit. No exceptions. Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

Disclosures

Faculty

- Ferguson, Sherry, Research Psychologist, Division of Neurotoxicology, NCTR/FDA - nothing to disclose
- Varma, Vijayalakshmi (Viji), Ph.D., Research Biologist, NCTR/FDA - nothing to disclose

Planning Committee

- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Lee, Christine - nothing to disclose
- Parish, Eileen, MD, Medical Officer, FDA/OC/OCS/OSPD - nothing to disclose
- Wheelock, Leslie, MS, RN, Director, OSPD, FDA, OC, OCS, OSPD - nothing to disclose

CE Consultation and the Accreditation Team

- Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds
Registration is complimentary; therefore, refunds are not applicable.

Remote Access Instructions ***Webcast Registration:*** To register for the webcast, please click the link below and then follow the instructions on the registration page. After you register you will receive a link via email to access the live webinar. You must log in with your username and password which you create when you register. Please pre-register at least one day before the event to ensure you receive the access link email and outlook invitation for the session.

LINK TO REGISTER for WEBCAST:
https://collaboration.fda.gov/grandroundsjan1118/event/registration.html

For technical assistance please contact Jeffery Rexrode at Jeffery.Rexrode@fda.hhs.gov.

HHS/LMS Registration Link for FDA employees
https://lms.learning.hhs.gov/Saba/Web/Main/goto/RegisterCatalog?offeringId=class000000000130811&oneClickLearningON=true

Reasonable Accommodations
The FDA provides reasonable accommodations for all individuals with disabilities who apply for training or developmental opportunities. If you need a reasonable accommodation for any part of the training application process, please notify the training contact for this particular event. Reasonable accommodation requests are granted on a case-by case basis. Should you need sign language interpretation to attend this event, please send the request to Interpreting.Services@oc.fda.gov.